Neisvac

N. meningitidis group C (strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid A, the active ingredient in Neisvac, is a vaccine presented as an injectable solution for intramuscular use. It induces active immunity to prevent invasive disease caused by Neisseria meningitidis serogroup C, primarily in adolescents and adults at risk.

GNH USA supplies Neisvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neisvac is a conjugate vaccine that targets the meningococcal serogroup C pathway to prevent serious bacterial infection. - Invasive meningococcal disease (serogroup C): provides active immunization to prevent infection and associated complications. - Outbreak control in communities: reduces transmission during serogroup C clusters. - Travel to endemic regions: offers protection for travelers at risk of exposure to serogroup C strains.

Neisvac may cause a range of post‑vaccination reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild to moderate headache. - Fatigue: temporary feeling of tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder. - Seizures: infrequent neurologic event. - Hypotension: sudden drop in blood pressure. - Severe local reaction: extensive necrosis or ulceration at injection site. - Serum sickness–like reaction: rash, arthralgia, and fever.

Before administering Neisvac, consider the following safety measures. - Pregnancy: safety not established; vaccinate only if benefit outweighs potential risk. - Breastfeeding: limited data; use with caution. - Immunocompromised patients: vaccine may be less effective; monitor response. - Known hypersensitivity: avoid in individuals allergic to any vaccine component. - Concurrent vaccines: can be given with other vaccines at separate sites. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac may interact with other agents that affect immune response.

Major Interactions (Avoid): - Immunoglobulin therapy: may diminish vaccine‑induced immunity if given simultaneously. - Blood products: can interfere with the development of protective antibodies.

Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): prophylactic use may reduce antibody response. - Other vaccines administered at the same site: may increase local reactogenicity. - Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may lower immunogenicity of the vaccine.